Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hypo-OPRA: Hypofractionated Pelvic RT for Rectal Cancer
NCT06991465Phase 2Recruiting
- Start
- Aug 2023
- Primary completion
- Sep 2027
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in rectal adenocarcinoma. Primary endpoint: Feasibility of Hypo-fractionated Approach in 5 fractions for a dose of 35Gy at 1 year. Started Aug 2023; status: recruiting.
02
Conditions
rectal adenocarcinoma
Beyond the preview
Go deeper on NCT06991465.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06991465.